A Randomized, Open Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigators Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Who Are Current or Former Smokers
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Veliparib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 06 Sep 2019 Planned End Date changed from 26 Jul 2019 to 4 Nov 2019.
- 06 Sep 2019 Planned primary completion date changed from 26 Jul 2019 to 31 Oct 2019.
- 31 Aug 2018 Biomarkers information updated